Moderna Stock News and Forecast: MRNA drops, but China could provide a catalyst
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get all exclusive analysis, access our analysis and get Gold and signals alerts
Elevate your trading Journey.
UPGRADE- Moderna stock collapses on Tuesday as the global equity sell-off gathers pace.
- MRNA closes over 6% lower on Tuesday.
- SPY closes 4% lower, while Nasdaq was 5% lower.
Moderna (MRNA) underperformed on Tuesday as a global equity rout took hold following higher-than-expected US inflation. The move in Moderna was to be expected, but the underperformance versus the main indices is a bit perplexing. Moderna is cash rich and would not be associated with long-duration stocks. Therefore, it would not fall into the yield-sensitive group of many other Nasdaq names. It was a high-growth story, yes, but now it has matured and so too have its cash flows. The company has an enormous pile of cash, which it will partly use for buyback and perhaps dividends in the future.
Moderna stock news
However, it is news from Reuters this morning that is capturing my attention. According to the report, Moderna CEO Stephane Bancel has spoken with the Chinese government about supplying its Covid-19 vaccine to China. As of yet, no decision has been made.
"We are open, [and] we have the capacity," CEO Bancel said. He was speaking in Tokyo where he also said Moderna is open to building manufacturing capacity to make mRNA products. Moderna has reportedly filed a lawsuit against Pfizer (PFE) and BioNTech (BNTX) for patent infringement involving cold vaccine development in the US.
Moderna says in its lawsuit that Pfizer and BioNTech's COVID-19 vaccine Comirnaty infringes on patents that Moderna filed between 2010 and 2016 covering mRNA technology.
The news over the lawsuit is too far out to generate any meaningful catalyst in my view. This could drag on for some time. However, any announcement of a deal with China would be a huge positive. It sounds like it may be a long shot, but with the world's largest population it would represent a massive opportunity for Moderna. As it stands, the company is well placed with cash of nearly $11 billion and little debt.
Moderna stock forecast
This is for now a short-term opportunity to perhaps bottom fish after Tuesday's sell-off and see if this story gets more legs to it. Moderna is perched precariously on support at $125, and a break will target then $100. This $120 to $125 zone has been held several times going back to March 2021, so it is key support.
MRNA daily chart
- Moderna stock collapses on Tuesday as the global equity sell-off gathers pace.
- MRNA closes over 6% lower on Tuesday.
- SPY closes 4% lower, while Nasdaq was 5% lower.
Moderna (MRNA) underperformed on Tuesday as a global equity rout took hold following higher-than-expected US inflation. The move in Moderna was to be expected, but the underperformance versus the main indices is a bit perplexing. Moderna is cash rich and would not be associated with long-duration stocks. Therefore, it would not fall into the yield-sensitive group of many other Nasdaq names. It was a high-growth story, yes, but now it has matured and so too have its cash flows. The company has an enormous pile of cash, which it will partly use for buyback and perhaps dividends in the future.
Moderna stock news
However, it is news from Reuters this morning that is capturing my attention. According to the report, Moderna CEO Stephane Bancel has spoken with the Chinese government about supplying its Covid-19 vaccine to China. As of yet, no decision has been made.
"We are open, [and] we have the capacity," CEO Bancel said. He was speaking in Tokyo where he also said Moderna is open to building manufacturing capacity to make mRNA products. Moderna has reportedly filed a lawsuit against Pfizer (PFE) and BioNTech (BNTX) for patent infringement involving cold vaccine development in the US.
Moderna says in its lawsuit that Pfizer and BioNTech's COVID-19 vaccine Comirnaty infringes on patents that Moderna filed between 2010 and 2016 covering mRNA technology.
The news over the lawsuit is too far out to generate any meaningful catalyst in my view. This could drag on for some time. However, any announcement of a deal with China would be a huge positive. It sounds like it may be a long shot, but with the world's largest population it would represent a massive opportunity for Moderna. As it stands, the company is well placed with cash of nearly $11 billion and little debt.
Moderna stock forecast
This is for now a short-term opportunity to perhaps bottom fish after Tuesday's sell-off and see if this story gets more legs to it. Moderna is perched precariously on support at $125, and a break will target then $100. This $120 to $125 zone has been held several times going back to March 2021, so it is key support.
MRNA daily chart
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.